Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lipella PharmaceuticalsLIPO -49.38% Debt-to-Equity is 0.18 as of Sep. 2025, which is 157% above its 10-year median of 0.07. The stock has 1 warning sign investors should review. Among 966 Biotechnology companies, Lipella Pharmaceuticals ranks worse than 51.66% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Lipella Pharmaceuticals's Debt-to-Equity or its related term are showing as below:
LIPO'
s Debt-to-Equity Range Over the Past 10 Years
Min: -3.86 Med: 0.07 Max: 0.84
Current: 0.18
During the past 5 years, the highest Debt-to-Equity Ratio of Lipella Pharmaceuticals was 0.84. The lowest was -3.86. And the median was 0.07.
LIPO's Debt-to-Equity is ranked worse than 51.66% of 966
companies
in the Biotechnology industry
Industry Median: 0.16
vs LIPO: 0.18
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Lipella Pharmaceuticals Debt-to-Equity Related Terms
Lipella Pharmaceuticals Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LIPO vs IOBTQ, WINT, CYTOF: Debt-to-Equity Comparison
For the Biotechnology subindustry, Lipella Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lipella Pharmaceuticals Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lipella Pharmaceuticals's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Lipella Pharmaceuticals's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lipella Pharmaceuticals (LIPO) has a Debt-to-Equity of 0.18 as of Sep. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Lipella Pharmaceuticals and its competitors. This is 157% above median its historical median of 0.07. According to the industry distribution chart, Lipella Pharmaceuticals ranks #499 out of 966 companies in the Biotechnology industry, placing it in the top 51.7%.
Is Lipella Pharmaceuticals' Debt-to-Equity too high?
Lipella Pharmaceuticals' current Debt-to-Equity of 0.18 is 157% above median its 10-year median of 0.07. The Biotechnology industry median Debt-to-Equity is 0.16. Lipella Pharmaceuticals' value of 0.18 is 12.5% above this industry median. Based on the distribution chart, Lipella Pharmaceuticals ranks #499 out of 966 companies in the Biotechnology industry, which is below the industry midpoint.
How does Lipella Pharmaceuticals' Debt-to-Equity compare to IOBTQ and WINT?
According to the Biotechnology industry distribution chart, Lipella Pharmaceuticals ranks #499 out of 966 companies for Debt-to-Equity. This places Lipella Pharmaceuticals in the lower half of its industry. The industry median Debt-to-Equity is 0.16. Lipella Pharmaceuticals' value of 0.18 is 12.5% above this benchmark. While the company's 10-year median is 0.07 vs. the industry median of 0.16, Lipella Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 966 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lipella Pharmaceuticals's current Debt-to-Equity of 0.18 is 12.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Lipella Pharmaceuticals and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lipella Pharmaceuticals's current Debt-to-Equity is 0.18, which is 157% above median its own 10-year median of 0.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lipella Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Lipella Pharmaceuticals (LIPO) is currently considered Possible Value Trap. The stock's GF Value™ is $8.74, compared to a current price of $0.03 — trading 99.6% below its estimated fair value. The current Debt-to-Equity is 0.18, which is 157% above median its 10-year median of 0.07 and 12.5% above the Biotechnology industry median of 0.16. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Lipella Pharmaceuticals (LIPO), the current Debt-to-Equity is 0.18 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Lipella Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. The company's product candidates include LP-10, LP-310 and LP-410, which can be helpful in the treatment of Hemorrahagic Cystitis, Oral Licen Planus and Oral Graft.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LIPO has been successfully added to your 
